| Melissa Maureen Hovey, CRNP | |
|
4370 W Main St, Dothan, AL 36305-1056 | |
| (334) 793-5000 | |
| Not Available |
| Full Name | Melissa Maureen Hovey |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 4370 W Main St, Dothan, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336419365 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 1-1146677 (Alabama) | Primary |
| Entity Name | App Of Alabama Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659646040 PECOS PAC ID: 3577725068 Enrollment ID: O20120430000174 |
News Archive
Patients who attend 'Heart School', as almost every patient in Sweden is invited to do after a first heart attack, live longer than non-participating patients. This is shown in a new study, by researchers at Uppsala University, published in the European Journal of Preventive Cardiology.
If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.
Bristol-Myers Squibb and Adnexus Therapeutics have announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins.
› Verified 4 days ago
| Entity Name | Southern Alabama Physicians, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467701490 PECOS PAC ID: 0345499562 Enrollment ID: O20121003000896 |
News Archive
Patients who attend 'Heart School', as almost every patient in Sweden is invited to do after a first heart attack, live longer than non-participating patients. This is shown in a new study, by researchers at Uppsala University, published in the European Journal of Preventive Cardiology.
If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.
Bristol-Myers Squibb and Adnexus Therapeutics have announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins.
› Verified 4 days ago
| Entity Name | Flowers Hb Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972283828 PECOS PAC ID: 6305290990 Enrollment ID: O20231002000205 |
News Archive
Patients who attend 'Heart School', as almost every patient in Sweden is invited to do after a first heart attack, live longer than non-participating patients. This is shown in a new study, by researchers at Uppsala University, published in the European Journal of Preventive Cardiology.
If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.
Bristol-Myers Squibb and Adnexus Therapeutics have announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Maureen Hovey, CRNP Po Box 6907, Dothan, AL 36302-6907 Ph: (334) 793-5000 | Melissa Maureen Hovey, CRNP 4370 W Main St, Dothan, AL 36305-1056 Ph: (334) 793-5000 |
News Archive
Patients who attend 'Heart School', as almost every patient in Sweden is invited to do after a first heart attack, live longer than non-participating patients. This is shown in a new study, by researchers at Uppsala University, published in the European Journal of Preventive Cardiology.
If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.
Bristol-Myers Squibb and Adnexus Therapeutics have announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins.
› Verified 4 days ago
Bethany Makayla Gilman, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1108 Ross Clark Cir, Dothan, AL 36301 Phone: 334-793-8111 | |
Pamela Galloway, RN, CLC, DOULA Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 799 Burkett Rd, Dothan, AL 36303 Phone: 334-798-3323 | |
Chelsea Nicole Kelley, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 302 Lakeview Dr, Dothan, AL 36301 Phone: 334-714-7778 | |
Mrs. Diana Phelps Golson, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 134 Prevatt Rd, Dothan, AL 36301 Phone: 334-794-0731 | |
Pamela Rose Wilder, NP Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 4370 W Main St, Dothan, AL 36305 Phone: 334-793-5000 | |
Mrs. Robin Gay Quire, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 134 Prevatt Rd, Dothan, AL 36301 Phone: 334-794-0731 | |
Mr. Jason Lee Cox, NP Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 4300 W Main St Ste 21, Dothan, AL 36305 Phone: 334-699-7900 |